Senti Biosciences Holdings (SNTI) Net Income towards Common Stockholders (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Net Income towards Common Stockholders of -$117.4 million for Q4 2025, down 547.45% quarter-over-quarter from -$18.1 million in Q3 2025.
Senti Biosciences Holdings (SNTI) Net Income towards Common Stockholders (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$117.4 million for Q4 2025.
- In Q4 2025, Net Income towards Common Stockholders changed N/A year-over-year to -$117.4 million; the TTM figure through Dec 2025 stood at -$164.3 million (down 214.93% YoY), while the FY2025 annual figure was -$167.5 million, changed N/A from the prior year.
- Net Income towards Common Stockholders for Q4 2025 stood at -$117.4 million, down from -$18.1 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $21.7 million in Q3 2023, with the low at -$117.4 million in Q4 2025.
- The 5-year median for Net Income towards Common Stockholders is -$11.4 million (2021), against an average of -$19.1 million.
- The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders plunged 996066.21% in 2022, then soared 1028.2% in 2023.
- Senti Biosciences Holdings' Net Income towards Common Stockholders stood at -$33.6 million in 2021, then surged by 74.54% to -$8.5 million in 2022, then soared by 99.67% to -$28000.0 in 2023, then sank by 102992.86% to -$28.9 million in 2024, then sank by 306.56% to -$117.4 million in 2025.
- Business Quant data shows SNTI's Net Income towards Common Stockholders at -$117.4 million in Q4 2025, -$18.1 million in Q3 2025, and -$14.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Senti Biosciences Holdings | 12.06 Mn | 12.06 Mn | - | -14.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -117.36 Mn |
| Sep 30, 2025 | -18.13 Mn |
| Jun 30, 2025 | -14.73 Mn |
| Mar 31, 2025 | -14.11 Mn |
| Sep 30, 2024 | -28.87 Mn |
| Jun 30, 2024 | -11.20 Mn |
| Mar 31, 2024 | -12.11 Mn |
| Dec 31, 2023 | -28,000.00 |
| Sep 30, 2023 | 21.69 Mn |
| Jun 30, 2023 | -4.45 Mn |
| Mar 31, 2023 | -4.87 Mn |
| Dec 31, 2022 | -8.55 Mn |
| Sep 30, 2022 | -2.34 Mn |
| Jun 30, 2022 | -82.14 Mn |
| Mar 31, 2022 | -11.73 Mn |
| Dec 31, 2021 | -33.57 Mn |
| Sep 30, 2021 | -11.42 Mn |
| Jun 30, 2021 | -9.00 Mn |
| Mar 31, 2021 | -1,178.00 |